Physician Behavioral Inertia: Innovation’s Greatest Enemy
Executive Summary
Overcoming Inertia is a challenge. Physicians want novel and better medications and products, but evaluating and trying new products takes time and may involve risk.
You may also be interested in...
Payer Power: What Are The Future Implications For Life Science Companies Developing New Products?
Payers cannot control the pricing of new products by biopharmaceutical companies, but their goal is to deliver quality health care in a cost-effective manner. Several payer medical directors representing over 100 million commercially insured members have shared their insights for managing the challenging US market – revealing their thoughts on drug pricing currently, and steps they plan to take in the next 3 to 5 years to better control rising costs.